Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 5,050 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 5,050 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $19.75, for a total value of $99,737.50. Following the completion of the transaction, the president directly owned 1,037,060 shares of the company’s stock, valued at approximately $20,481,935. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Arcus Biosciences Price Performance

Shares of RCUS stock traded up $0.91 during mid-day trading on Thursday, reaching $21.13. The company’s stock had a trading volume of 347,451 shares, compared to its average volume of 1,093,605. The firm’s 50-day moving average is $16.25 and its two-hundred day moving average is $11.81. The company has a market cap of $2.28 billion, a P/E ratio of -6.12 and a beta of 0.90. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $22.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. During the same quarter last year, the company earned ($1.00) earnings per share. The company’s revenue for the quarter was down 45.8% compared to the same quarter last year. On average, research analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RCUS. HC Wainwright boosted their target price on shares of Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Citigroup raised their price objective on shares of Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Wells Fargo & Company raised their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Finally, Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $28.44.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in RCUS. Bank of New York Mellon Corp increased its position in Arcus Biosciences by 5.2% in the first quarter. Bank of New York Mellon Corp now owns 401,570 shares of the company’s stock worth $3,152,000 after purchasing an additional 19,955 shares during the period. Arizona State Retirement System lifted its holdings in Arcus Biosciences by 34.3% in the first quarter. Arizona State Retirement System now owns 19,604 shares of the company’s stock valued at $154,000 after buying an additional 5,010 shares during the period. Louisiana State Employees Retirement System boosted its stake in Arcus Biosciences by 21.5% in the first quarter. Louisiana State Employees Retirement System now owns 31,700 shares of the company’s stock valued at $249,000 after acquiring an additional 5,600 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Arcus Biosciences by 36.4% during the 1st quarter. Victory Capital Management Inc. now owns 62,340 shares of the company’s stock worth $489,000 after acquiring an additional 16,622 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Arcus Biosciences during the 1st quarter valued at $247,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.